|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.31 USD | -0.87% |
|
-0.72% | -29.81% |
| Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
| Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
Veracyte, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 4.15 million compared to USD 6.8 million a year ago. Revenue was USD 98.2 million compared to USD 80.3 million a year ago.
Net loss was USD 28.29 million compared to USD 3.84 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.05 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -29.81% | 1.48B | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 377M | |
| +13.32% | 332M |
VERACYTE, INC. 
